◀ Back to IL2
HLA-A — IL2
Pathways - manually collected, often from reviews:
Text-mined interactions from Literome
Correale et al., Br J Cancer 2001
(Bone Neoplasms...) :
In this model, we investigated the in vitro possibility of generating an efficient PTH-rP specific CTL response by cyclical
stimulations with
IL-2 and PTR-4 peptide pulsed autologous dendritic cells ( DC ), of
HLA-A2.1 ( + ) tumour infiltrating lymphocytes (TIL) derived from a patient with metastatic prostate carcinoma
Willemsen et al., J Immunol 2005
(Melanoma) :
Human scFv-G8 ( POS ) T lymphocytes comprising the gamma + CD28 vs the gamma signaling element alone produced substantially more
IL-2 , TNF-alpha, and IFN-gamma in
response to
HLA-A1/MAGE-A1 ( POS ) melanoma cells
De Felice et al., J Immunol 1987
:
Distinct determinants of HLA class I antigens regulate T cell proliferation by different mechanisms, because the
anti-HLA-A2 , A28 mAb CR11-351, and the mAb W6/32 to a framework determinant of HLA class I antigens
block interleukin 2 (IL-2) secretion and
IL-2 receptor expression, whereas the mAb CR10-215 to a monomorphic determinant blocks only IL-2 receptor expression
Todd et al., Clin Exp Immunol 1985
:
All three IFN, but not
IL-2 ,
enhanced thyroid cell
HLA-A , B,C expression